(TBRG) TruBridge - Ratings and Ratios
Rcm, Billing, EHR, Tech, Consulting
TBRG EPS (Earnings per Share)
TBRG Revenue
Description: TBRG TruBridge
TruBridge Inc. (NASDAQ:TBRG) is a healthcare technology company that provides a comprehensive suite of solutions and services to community hospitals, clinics, and healthcare systems. The companys two main segments, Financial Health and Patient Care, focus on revenue cycle management, analytics, and business intelligence, aiming to improve patient outcomes and financial performance for healthcare providers.
The companys offerings include a range of services such as patient liability estimate, eligibility verification, claim scrubbing, and remittance management, as well as consulting and business management services, managed IT services, and encoder solutions. Additionally, TruBridge provides acute care software systems, patient engagement and empowerment technology solutions, and data analytics platforms like CHBase, which aggregates data from multiple sources into one platform.
From a performance perspective, key metrics to watch include revenue growth, customer acquisition rates, and the percentage of revenue derived from recurring services. The companys ability to expand its customer base and increase revenue from existing clients will be crucial in driving growth. Furthermore, the effectiveness of its RCM solutions in improving healthcare providers financial performance and the adoption rate of its patient engagement and empowerment technologies will be important KPIs to monitor.
Given the companys focus on healthcare technology and its comprehensive suite of solutions, TruBridges competitive positioning and market share in the RCM and healthcare IT markets are also significant factors to consider. The companys ability to innovate and expand its offerings to meet evolving healthcare needs will be critical in maintaining its competitive edge.
With a market capitalization of $343.28M USD and a forward P/E ratio of 9.81, investors will be watching the companys ability to deliver on its growth prospects and improve its return on equity, which currently stands at -9.99%. The companys financial performance, operational efficiency, and strategic initiatives will be closely monitored to assess its potential for long-term success.
TBRG Stock Overview
| Market Cap in USD | 302m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2002-05-21 |
TBRG Stock Ratings
| Growth Rating | 2.14% |
| Fundamental | 65.4% |
| Dividend Rating | 16.7% |
| Return 12m vs S&P 500 | 39.9% |
| Analyst Rating | 4.0 of 5 |
TBRG Dividends
Currently no dividends paidTBRG Growth Ratios
| Growth Correlation 3m | -88.3% |
| Growth Correlation 12m | 55% |
| Growth Correlation 5y | -70.6% |
| CAGR 5y | -6.14% |
| CAGR/Max DD 5y | -0.08 |
| Sharpe Ratio 12m | 1.61 |
| Alpha | 57.12 |
| Beta | 0.513 |
| Volatility | 40.04% |
| Current Volume | 40.2k |
| Average Volume 20d | 99.8k |
| Stop Loss | 19 (-4.8%) |
| Signal | -2.40 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (-12.4m TTM) > 0 and > 6% of Revenue (6% = 20.9m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 10.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.53% (prev 11.85%; Δ -0.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 34.9m > Net Income -12.4m (YES >=105%, WARN >=100%) |
| Net Debt (-7.47m) to EBITDA (47.2m) ratio: -0.16 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (14.5m) change vs 12m ago 1.46% (target <= -2.0% for YES) |
| Gross Margin 57.30% (prev 44.01%; Δ 13.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 86.64% (prev 81.63%; Δ 5.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.79 (EBITDA TTM 47.2m / Interest Expense TTM 7.54m) >= 6 (WARN >= 3) |
Altman Z'' 0.87
| (A) 0.10 = (Total Current Assets 90.3m - Total Current Liabilities 50.2m) / Total Assets 390.2m |
| (B) -0.03 = Retained Earnings (Balance) -11.9m / Total Assets 390.2m |
| (C) 0.05 = EBIT TTM 21.0m / Avg Total Assets 401.2m |
| (D) -0.05 = Book Value of Equity -11.9m / Total Liabilities 217.0m |
| Total Rating: 0.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.36
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 4.51% = 2.26 |
| 3. FCF Margin 5.92% = 1.48 |
| 4. Debt/Equity 0.96 = 2.06 |
| 5. Debt/Ebitda 3.52 = -2.32 |
| 6. ROIC - WACC 7.00% = 8.75 |
| 7. RoE -7.23% = -1.21 |
| 8. Rev. Trend 46.17% = 2.31 |
| 9. Rev. CAGR 1.26% = 0.16 |
| 10. EPS Trend -13.09% = -0.33 |
| 11. EPS CAGR 7.00% = 0.70 |
What is the price of TBRG shares?
Over the past week, the price has changed by -2.54%, over one month by -8.61%, over three months by -16.17% and over the past year by +63.61%.
Is TruBridge a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TBRG is around 18.69 USD . This means that TBRG is currently overvalued and has a potential downside of -6.36%.
Is TBRG a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TBRG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.8 | 24% |
| Analysts Target Price | 24.8 | 24% |
| ValueRay Target Price | 20.7 | 3.9% |
Last update: 2025-08-28 04:52
TBRG Fundamental Data Overview
CCE Cash And Equivalents = 12.3m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 9.8135
P/S = 0.8733
P/B = 1.7346
P/EG = 0.88
Beta = 0.594
Revenue TTM = 347.6m USD
EBIT TTM = 21.0m USD
EBITDA TTM = 47.2m USD
Long Term Debt = 163.1m USD (from longTermDebt, last quarter)
Short Term Debt = 2.98m USD (from shortTermDebt, last quarter)
Debt = 166.1m USD (Calculated: Short Term 2.98m + Long Term 163.1m)
Net Debt = -7.47m USD (from netDebt column, last quarter)
Enterprise Value = 455.8m USD (302.0m + Debt 166.1m - CCE 12.3m)
Interest Coverage Ratio = 2.79 (Ebit TTM 21.0m / Interest Expense TTM 7.54m)
FCF Yield = 4.51% (FCF TTM 20.6m / Enterprise Value 455.8m)
FCF Margin = 5.92% (FCF TTM 20.6m / Revenue TTM 347.6m)
Net Margin = -3.55% (Net Income TTM -12.4m / Revenue TTM 347.6m)
Gross Margin = 57.30% ((Revenue TTM 347.6m - Cost of Revenue TTM 148.4m) / Revenue TTM)
Tobins Q-Ratio = -38.40 (set to none) (Enterprise Value 455.8m / Book Value Of Equity -11.9m)
Interest Expense / Debt = 1.85% (Interest Expense 3.06m / Debt 166.1m)
Taxrate = -269.6% (set to none) (from quarterly Income Tax Expense: -1.88m / 698.0k)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.80 (Total Current Assets 90.3m / Total Current Liabilities 50.2m)
Debt / Equity = 0.96 (Debt 166.1m / last Quarter total Stockholder Equity 173.2m)
Debt / EBITDA = 3.52 (Net Debt -7.47m / EBITDA 47.2m)
Debt / FCF = 8.07 (Debt 166.1m / FCF TTM 20.6m)
Total Stockholder Equity = 170.8m (last 4 quarters mean)
RoA = -3.17% (Net Income -12.4m, Total Assets 390.2m )
RoE = -7.23% (Net Income TTM -12.4m / Total Stockholder Equity 170.8m)
RoCE = 6.29% (Ebit 21.0m / (Equity 170.8m + L.T.Debt 163.1m))
RoIC = 7.00% (Ebit 21.0m / (Assets 390.2m - Current Assets 90.3m))
WACC = unknown (E(302.0m)/V(468.1m) * Re(7.91%)) + (D(166.1m)/V(468.1m) * Rd(1.85%) * (1-Tc(none)))
Shares Correlation 5-Years: 30.0 | Cagr: 0.28%
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈20.6m ; Y1≈13.5m ; Y5≈6.18m
Fair Price DCF = 8.09 (DCF Value 121.4m / Shares Outstanding 15.0m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 46.17 | Revenue CAGR: 1.26%
Rev Growth-of-Growth: -10.05
EPS Correlation: -13.09 | EPS CAGR: 7.00%
EPS Growth-of-Growth: 276.5
Additional Sources for TBRG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle